9 results on '"M. Martea"'
Search Results
2. High-performance liquid chromatography of sulphadimethoxine and its N1-glucuronide, N4-acetyl and N4-acetyl-N1-glucuronide metabolites in human plasma and urine
- Author
-
Tom B. Vree, E. W. J. Beneken Kolmer, Minoru Shimoda, R. Bosch, and M. Martea
- Subjects
Chromatography ,Chemistry ,Sulfadimethoxine ,Glucuronates ,General Chemistry ,Urine ,High-performance liquid chromatography ,Capacity factor ,Human plasma ,Gradient system ,Humans ,Moiety ,Glucuronide ,Chromatography, High Pressure Liquid - Abstract
Sulphadimethoxine is metabolized in humans by N1-glucuronidation and by N4-acetylation. Sulphadimethoxine-N1-glucuronide can be measured by the direct high-performance liquid chromatographic analysis and without enzymic deglucuronidation. The N1-glucuronide can be measured by an isocratic as well as by a gradient mobile phase. The group contribution of the N1-glucuronide moiety to the capacity factor is a reduction of 0.24 in the isocratic system and 0.55 in the gradient system. N4-Acetylation increases the capacity factor by a factor 1.4 in the isocratic system and by 1.06 in the gradient system.
- Published
- 1990
- Full Text
- View/download PDF
3. Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis
- Author
-
M. Martea, Yechiel A. Hekster, A. J. Voets, J. H. M. Berden, and Tom B. Vree
- Subjects
Male ,medicine.medical_specialty ,Sulfamethoxazole ,Anti-Infective Agents, Urinary ,Urology ,Pharmaceutical Science ,Peritonitis ,Trimethoprim ,Peritoneal Dialysis, Continuous Ambulatory ,Pharmacokinetics ,Oral administration ,Cefradine ,Trimethoprim, Sulfamethoxazole Drug Combination ,medicine ,Humans ,Pharmacology (medical) ,Cephradine ,Pharmacology ,business.industry ,Continuous ambulatory peritoneal dialysis ,Middle Aged ,medicine.disease ,Cephalosporins ,Surgery ,Drug Combinations ,Kinetics ,Kidney Failure, Chronic ,Capd peritonitis ,business ,Half-Life ,Protein Binding ,medicine.drug - Abstract
Cefradine and co-trimoxazole pharmacokinetics were studied in a patient with peritonitis that complicated continuous ambulatory peritoneal dialysis (CAPD). Concentrations in the plasma reached after oral administration of 500 mg cefradine four times daily and 400/80 mg co-trimoxazole four times daily were for cefradine 100 micrograms/ml, for trimethoprim 15 micrograms/ml, and for sulfamethoxazole 100 micrograms/ml, respectively. In the dialysate concentrations were reached of 35-70 micrograms/ml cefradine, 2-5 micrograms/ml trimethoprim and 8-17 micrograms/ml sulfamethoxazole. The values for sulfamethoxazole are regarded too low to be clinically effective. Half-lives, protein binding values and CAPD clearances are presented. Low CAPD clearances were obtained during the night and high values during the day. The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low. It seems questionable therefore whether co-trimoxazole can be used orally for the treatment of CAPD peritonitis.
- Published
- 1987
- Full Text
- View/download PDF
4. Deterioration of kidney function by high doses of co-trimoxazole in man
- Author
-
Yechiel A. Hekster, M. Martea, J. H. M. Berden, R. Van Klaveren, Jan Willem J. Lammers, Tom B. Vree, and E. F. S. Termond
- Subjects
Adult ,Male ,Drug ,medicine.medical_specialty ,Sulfamethoxazole ,media_common.quotation_subject ,Anti-Infective Agents, Urinary ,Renal function ,urologic and male genital diseases ,Trimethoprim ,Pharmacokinetics ,Internal medicine ,Trimethoprim, Sulfamethoxazole Drug Combination ,medicine ,Crystalluria ,High doses ,Humans ,Pharmacology (medical) ,media_common ,Pharmacology ,business.industry ,Pneumonia, Pneumocystis ,Drug Combinations ,Kinetics ,Endocrinology ,Kidney Diseases ,medicine.symptom ,business ,Kidney tubules ,medicine.drug - Abstract
High doses of co-trimoxazole in a patient with Pneumocystis carinii and impaired kidney function (creatinine clearance 10 ml/min) resulted in a declining renal clearance of the drug but did not affect the average creatinine clearance. The renal clearance of sulfamethoxazole and its metabolites 5-hydroxy-, N4-acetyl-, N4-acetyl-5-hydroxysulfamethoxazole decreased 80%, while the renal clearance of trimethoprim decreased 60%. The renal clearance of all compounds was evidently dependent on urine flow. The observed phenomena may be explained by the assumption that crystalluria occurred, obstructing kidney tubules. The crystalluria effect can be reversed by cessation of the drug or by lowering its dosage.
- Published
- 1987
- Full Text
- View/download PDF
5. Pharmacokinetics of Theophylline and its Metabolites in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis
- Author
-
Jan C. M. Hafkenscheid, M. Martea, Tom B. Vree, R. G. W. L. Tiggeler, and Yechiel A. Hekster
- Subjects
Male ,medicine.medical_specialty ,Low protein ,medicine.drug_class ,Metabolite ,Renal function ,urologic and male genital diseases ,chemistry.chemical_compound ,Peritoneal Dialysis, Continuous Ambulatory ,Theophylline ,Pharmacokinetics ,Bronchodilator ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Aged ,Pharmacology ,Creatinine ,business.industry ,Continuous ambulatory peritoneal dialysis ,female genital diseases and pregnancy complications ,Uric Acid ,Endocrinology ,chemistry ,Xanthines ,Kidney Failure, Chronic ,business ,medicine.drug - Abstract
Absence of kidney function results in high steady-state plasma concentrations of the theophylline metabolites. The CAPD clearance of theophylline and its metabolites is correlated with the CAPD clearance of creatinine. N-demethylation of theophylline results in a higher CAPD clearance of these metabolites than that of the parent drug. The relatively low protein binding values of theophylline and its metabolites can be explained by the low albumin concentration.
- Published
- 1988
- Full Text
- View/download PDF
6. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
- Author
-
Wijnands GJ, Cornel JH, Martea M, and Vree TB
- Subjects
- 4-Quinolones, Administration, Oral, Adult, Anti-Infective Agents pharmacokinetics, Anti-Infective Agents pharmacology, Drug Administration Schedule, Drug Interactions, Female, Humans, Injections, Intravenous, Kidney metabolism, Male, Theophylline administration & dosage, Theophylline pharmacokinetics, Anti-Infective Agents administration & dosage, Fluoroquinolones, Quinolones, Theophylline metabolism
- Abstract
Single-dose plasma pharmacokinetics of theophylline (6 mg/kg intravenously) and renal excretion of theophylline and its metabolites, resulting from 8-oxidation and N-demethylation, were investigated in eight healthy volunteers before and at day 3 of concomitant oral administration of the quinolone derivative lomefloxacin (400 mg twice daily). Plasma samples were collected until 24.5 h, and urine samples were collected until 72 h after theophylline administration. The concentrations of theophylline and the major metabolites, resulting from N-demethylation and 8-oxidation, were measured utilizing a high-pressure liquid chromatography (HPLC) technique. No significant changes in theophylline half-life, volume of distribution, protein binding, total body clearance, or renal clearance were noted. In addition, renal excretion of unchanged theophylline, the products of the N-demethylation, 3-methylxanthine, and 1-methyluric acid, and the product of the 8-oxidation, 1,3-dimethyluric acid, were not altered by simultaneous administration of lomefloxacin. Orally administered lomefloxacin is absorbed quickly and to a high extent. During administration of 400 mg twice daily, plasma concentrations reached are well above minimum inhibitory concentration (MIC) values of pathogens that are frequently isolated in lower respiratory tract infections. This study shows that lomefloxacin in a twice daily dose of 400 mg does not effect theophylline metabolism. Lomefloxacin and theophylline can be coadministered without concern about effects of lomefloxacin on theophylline pharmacokinetics.
- Published
- 1990
- Full Text
- View/download PDF
7. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in man.
- Author
-
Vree TB, Beneken Kolmer EW, Martea M, Bosch R, Hekster YA, and Shimoda M
- Subjects
- Acetylation, Adult, Chromatography, High Pressure Liquid, Dealkylation, Female, Glucuronates metabolism, Half-Life, Humans, Male, Middle Aged, Phenotype, Protein Binding, Sulfadimethoxine pharmacokinetics, Sulfadimethoxine urine, Sulfadimethoxine metabolism
- Abstract
Sulfadimethoxine is metabolized by O-dealkylation, N4-acetylation and N1-glucuronidation. In man, only N1-glucuronidation and N4-acetylation takes place, leading to the final double conjugate N4-acetylsulfadimethoxine-N1-glucuronide. The N1-glucuronides are directly measured by high pressure liquid chromatography. When N4-acetylsulfadimethoxine is administered as parent drug, 30% of the dose is N1-glucuronidated and excreted. Fast acetylators show a shorter half-life for sulfadimethoxine than slow acetylators (27.8 +/- 4.2 h versus 36.3 +/- 5.4 h; P = 0.013), similarly the half-life of the N4-acetyl conjugate is also shorter in fast acetylators (41.3 +/- 5.2 h versus 53.5 +/- 8.5 h, P = 0.036). No measurable plasma concentrations of the N1-glucuronides from sulfadimethoxine are found in plasma. N1-glucuronidation results in a 75% decrease in protein binding of sulfadimethoxine. N4-acetylsulfadimethoxine and its N1-glucuronide showed the same high protein binding of 99%. Approximately 50-60% of the oral dose of sulfadimethoxine is excreted in the urine, leaving 40-50% for excretion into bile and faeces.
- Published
- 1990
- Full Text
- View/download PDF
8. Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.
- Author
-
Martea M, Hekster YA, Vree TB, Voets AJ, and Berden JH
- Subjects
- Anti-Infective Agents, Urinary therapeutic use, Anti-Infective Agents, Urinary urine, Cephradine therapeutic use, Cephradine urine, Drug Combinations metabolism, Drug Combinations therapeutic use, Drug Combinations urine, Half-Life, Humans, Kidney Failure, Chronic metabolism, Kidney Failure, Chronic therapy, Kinetics, Male, Middle Aged, Peritonitis drug therapy, Peritonitis etiology, Protein Binding, Sulfamethoxazole therapeutic use, Sulfamethoxazole urine, Trimethoprim therapeutic use, Trimethoprim urine, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Infective Agents, Urinary metabolism, Cephalosporins metabolism, Cephradine metabolism, Peritoneal Dialysis, Continuous Ambulatory adverse effects, Peritonitis metabolism, Sulfamethoxazole metabolism, Trimethoprim metabolism
- Abstract
Cefradine and co-trimoxazole pharmacokinetics were studied in a patient with peritonitis that complicated continuous ambulatory peritoneal dialysis (CAPD). Concentrations in the plasma reached after oral administration of 500 mg cefradine four times daily and 400/80 mg co-trimoxazole four times daily were for cefradine 100 micrograms/ml, for trimethoprim 15 micrograms/ml, and for sulfamethoxazole 100 micrograms/ml, respectively. In the dialysate concentrations were reached of 35-70 micrograms/ml cefradine, 2-5 micrograms/ml trimethoprim and 8-17 micrograms/ml sulfamethoxazole. The values for sulfamethoxazole are regarded too low to be clinically effective. Half-lives, protein binding values and CAPD clearances are presented. Low CAPD clearances were obtained during the night and high values during the day. The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low. It seems questionable therefore whether co-trimoxazole can be used orally for the treatment of CAPD peritonitis.
- Published
- 1987
- Full Text
- View/download PDF
9. Deterioration of kidney function by high doses of co-trimoxazole in man.
- Author
-
Vree TB, Martea M, Hekster YA, Termond EF, Van Klaveren R, Lammers JW, and Berden JH
- Subjects
- Adult, Anti-Infective Agents, Urinary blood, Anti-Infective Agents, Urinary therapeutic use, Drug Combinations adverse effects, Drug Combinations blood, Drug Combinations therapeutic use, Humans, Kinetics, Male, Pneumonia, Pneumocystis drug therapy, Sulfamethoxazole blood, Sulfamethoxazole therapeutic use, Trimethoprim blood, Trimethoprim therapeutic use, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Infective Agents, Urinary adverse effects, Kidney Diseases chemically induced, Sulfamethoxazole adverse effects, Trimethoprim adverse effects
- Abstract
High doses of co-trimoxazole in a patient with Pneumocystis carinii and impaired kidney function (creatinine clearance 10 ml/min) resulted in a declining renal clearance of the drug but did not affect the average creatinine clearance. The renal clearance of sulfamethoxazole and its metabolites 5-hydroxy-, N4-acetyl-, N4-acetyl-5-hydroxysulfamethoxazole decreased 80%, while the renal clearance of trimethoprim decreased 60%. The renal clearance of all compounds was evidently dependent on urine flow. The observed phenomena may be explained by the assumption that crystalluria occurred, obstructing kidney tubules. The crystalluria effect can be reversed by cessation of the drug or by lowering its dosage.
- Published
- 1987
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.